Murakami, Yasushi
Shindo, Yuichiro
Sano, Masahiro
Okumura, Junya
Kobayashi, Hironori
Sakakibara, Toshihiro
Iguchi, Mitsutaka
Takahashi, Kunihiko
Yagi, Tetsuya
Matsui, Shigeyuki
Hasegawa, Yoshinori
Funding for this research was provided by:
Japan Society for the Promotion of Science (20K08517)
Article History
Received: 28 April 2022
Accepted: 19 August 2022
First Online: 26 August 2022
Competing interests
: The following information describes relevant financial activities outside of the submitted work. YS reports personal fees (payment for lectures, including service on speakers bureaus) from KYORIN Pharmaceutical Co., Ltd., AstraZeneca K.K., DAIICHI SANKYO COMPANY, LIMITED, Nippon Boehringer Ingelheim Co., Ltd., GlaxoSmithKline plc, and Gilead Sciences Inc. and participates as a member of the case adjudication committee of GlaxoSmithKline Biologicals SA. TY reports grants and personal fees (payment for lectures, including service on speakers bureaus) from Shionogi & Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., and MSD K.K. SM reports personal fees (payment for consultations in other studies) from Takeda Pharmaceutical Co., Ltd. YH reports grants and personal fees (payment for lectures, including service on speakers bureaus) from Chugai Pharmaceutical Co., Ltd., MSD K.K., GlaxoSmithKline plc, KYORIN Pharmaceutical Co., Ltd., Pfizer Japan Inc., Meiji Seika Pharma Co, Ltd., Sanofi K.K., and Daiichi Sankyo, Inc. All other authors have nothing to declare. The funders had no roles in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.